Search
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalIt is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Synonyms: -GLUTAMYL-L-TYROSYL-L-PROLYL-(2S)-2-CYCLOHEXYLGLYCYL-N6-(3, -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigational[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. … [A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: TERFAMEX TPivmecillinam
go.drugbank.com/drugs/DB01605ApprovedInvestigationalPivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDefibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIt has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). … Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA.
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalby Alkermes Inc. … Samidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction.
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage … [A20302] Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather
Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
E3 ubiquitin-protein ligase HUWE1
go.drugbank.com/bio_entities/BE0016469TargetHumansUbiquitinates MFN2 to negatively regulate mitochondrial fusion in response to decreased stearoylation of TFRC (PubMed:26214738). … 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains protect 'Lys-63'-linkages from CYLD deubiquitination (PubMed:27746020). Ubiquitinates PPARA in hepatocytes (By similarity)
Synonyms: Homologous to E6AP carboxyl terminus homologous protein 9Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Categories: Agents to Treat Airway Disease